For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Hyperkalemia is a potentially life-threatening condition in which serum potassium concentration exceeds 5.5 mEq/L. Despite various guidelines, no accepted consensus exists for the management of hyperkalemia. The aggressiveness of therapy is dependent on the rapidity with which hyperkalemia develops and absolute K+ concentration. Clinicians manage this condition in two ways: increasing K+ cell uptake (IV insulin / glucose, inhaled salbutamol) and/or increasing potassium excretion (K+ binders, diuretics). In this report, we look at the key therapies and how they are being used in the treatment of newly diagnosed and recently treated hyperkalemia patients. This report also dives into the compliance and persistency rates of drug-treated patients at the product level.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AstraZeneca, Vifor Pharma
Key drugs: Lokelma, Veltassa
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.